sever
fever
thrombocytopenia
syndrom
sft
emerg
febril
ill
caus
novel
phleboviru
sft
bunyaviru
sftsv
sft
character
sudden
onset
hyperpyrexia
respiratori
gastrointestin
symptom
leukocytopenia
thrombocytopenia
neurolog
symptom
possibl
even
death
within
day
onset
diseas
report
fatal
rate
vari
date
neither
effect
antivir
strategi
convent
vaccin
achiev
sustain
control
spread
sftsv
better
understand
mechan
underli
sft
progress
help
develop
new
prevent
therapeut
strategi
although
mechan
sft
incomplet
understood
accept
immun
system
may
play
import
role
previou
studi
demonstr
immun
cell
monocyt
myeloid
plasmacytoid
dendrit
cell
peripher
blood
also
dramat
decreas
acut
sft
patient
especi
deceas
patient
previou
studi
demonstr
lymphocyt
cellular
red
pulp
decreas
spleen
sftsvinfect
mice
first
week
inocul
addit
report
show
cell
decreas
acut
phase
patient
eventu
die
diseas
howev
almost
previou
studi
collect
sampl
one
two
time
point
diseas
process
rather
determin
dynam
chang
surviv
deceas
patient
studi
correl
cell
diseas
sever
exist
addit
role
tcell
subset
sft
progress
remain
unclear
cell
subdivid
multipl
subset
includ
helper
regulatori
cell
treg
defin
characterist
cytokin
product
profil
cell
defin
abil
secret
cytokin
tumour
necrosi
factor
alpha
play
critic
role
immun
respons
mani
viral
infect
cell
critic
promot
antihelminth
immun
allerg
inflamm
product
interleukin
cell
recent
discov
popul
helper
cell
implic
drive
harm
inflamm
autoimmun
cell
may
contribut
immunolog
injuri
respons
virus
produc
hallmark
cytokin
treg
maintain
immun
homeostasi
limit
magnitud
immun
respons
pathogen
control
inflammatori
reaction
secret
antiinflammatori
cytokin
total
count
tcell
subset
decreas
function
lost
abil
cell
mediat
viral
remov
provid
help
b
cell
regul
immunopatholog
damag
addit
becom
increasingli
clear
consider
plastic
exist
within
tcell
subset
vivo
especi
respons
pathogen
previou
studi
suggest
balanc
critic
mainten
immun
cell
homeostasi
number
differ
autoimmun
diseas
viral
infect
deep
understand
chang
treg
sft
patient
need
develop
effect
antivir
strategi
immun
regul
method
elimin
viru
protect
host
excess
inflammatori
damag
present
studi
measur
dynam
chang
frequenc
lymphocyt
tcell
subset
deceas
surviv
patient
throughout
entir
cours
infect
addit
correl
lymphocyt
tcell
subset
frequenc
sft
index
sftsi
evalu
result
suggest
tlymphocyt
defici
tcell
subset
imbal
potenti
play
import
role
sft
pathogenesi
inform
use
promot
indepth
investig
mechan
sftsv
pathogenesi
may
provid
immun
basi
new
therapeut
strategi
research
ethic
committe
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
wuhan
china
approv
studi
enrol
particip
provid
inform
written
consent
enter
studi
prior
blood
collect
may
septemb
patient
sftsv
infect
accord
clinic
guidelin
sft
releas
ministri
health
peopl
republ
china
admit
union
hospit
wuhan
citi
individu
concurr
hepat
c
viru
hepat
b
viru
human
immunodefici
viru
hiv
infect
epsteinbarr
viru
infect
patient
met
clinic
biolog
criteria
bacteri
fungal
infect
exclud
patient
admit
hospit
day
onset
ill
studi
protocol
approv
ethic
committe
unit
written
inform
consent
obtain
subject
patient
detail
includ
clinic
histori
physic
examin
find
routin
haematolog
laboratori
result
collect
medic
record
conduct
retrospect
analysi
basic
characterist
subject
admiss
list
tabl
sftsvinfect
patient
receiv
standard
antivir
support
treatment
admiss
hospit
base
sft
treatment
guidelin
chines
ministri
health
sequenti
blood
sampl
collect
regular
interv
within
h
admiss
everi
three
day
thereaft
day
discharg
addit
consid
patient
blood
test
result
first
day
admiss
within
day
diseas
onset
acut
phase
patient
blood
test
result
day
discharg
two
week
diseas
onset
clinic
symptom
begin
resolv
laboratori
measur
gradual
revert
normal
recoveri
phase
fifteen
sftsvuninfect
blood
donor
background
diseas
match
infect
patient
regard
sex
age
ethnic
background
enrol
present
studi
blood
sampl
collect
singl
time
point
time
enrol
sampl
process
within
first
h
collect
peripher
blood
mononuclear
cell
pbmc
separ
via
densiti
gradient
centrifug
ficollpaqu
plu
dakew
biotech
china
accord
manufactur
instruct
measur
intracellular
cytokin
pbmc
stimul
pma
ngml
sigmaaldrich
usa
ionomycin
sigmaaldrich
presenc
brefeldin
mg
ml
ebiosci
usa
h
cultur
stimul
pbmc
collect
tube
surfac
stain
biolegend
usa
biolegend
biolegend
antibodi
well
efluor
fixabl
viabil
dye
ebiosci
min
cell
treat
fix
perm
reagent
ebiosci
follow
intracellular
stain
pelabel
ebiosci
apclabel
ebiosci
ebiosci
analysi
treg
pbmc
collect
tube
without
pma
bfa
ionomycin
stimul
surfac
stain
biolegend
biolegend
biolegend
biolegend
antibodi
well
efluor
fixabl
viabil
dye
ebiosci
min
wash
twice
phosphatebuff
salin
pb
hyclon
usa
subsequ
sampl
resuspend
pb
acquisit
facscalibur
flow
cytomet
bd
bioscienc
approxim
event
per
tube
acquir
via
flow
cytometri
determin
frequenc
circul
lymphocyt
result
analys
flowjo
softwar
tree
star
ashland
usa
absolut
number
obtain
multipli
number
lymphocyt
venou
peripher
blood
percentag
tcell
subset
follow
low
treg
describ
previous
total
rna
extract
everi
clinic
patient
serum
specimen
use
viral
rna
kit
daan
gene
guangzhou
china
viral
load
sftsv
rna
copi
paramet
monitor
indic
time
point
entir
hospit
stay
patient
dash
line
repres
median
uninfect
control
data
shown
median
ci
statist
analysi
perform
use
mannwhitney
u
test
wilcoxon
match
pair
test
level
signific
indic
follow
ns
signific
p
p
p
p
sft
patient
determin
use
certifi
realtim
pcr
kit
sfda
registr
china
accord
manufactur
instruct
concentr
biolegend
usa
well
r
usa
serum
sft
patient
measur
elisa
use
commerci
kit
accord
manufactur
instruct
detect
limit
cytokin
follow
pgml
pgml
pgml
pgml
report
previous
sftsi
patient
admiss
sftsi
neurolog
symptom
level
respiratori
symptom
level
viral
load
ln
monocyt
use
evalu
sever
sft
result
analys
use
spss
version
spss
inc
chicago
il
usa
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
continu
variabl
summar
median
rang
median
ci
dichotom
variabl
specifi
use
absolut
valu
percentag
two
independ
group
twotail
mannwhitney
u
test
perform
singl
comparison
pair
sampl
twotail
wilcoxon
match
pair
test
perform
dichotom
variabl
tabl
analys
use
fisher
exact
test
correl
analysi
continu
variabl
perform
use
nonparametr
spearman
correl
test
test
twotail
pvalu
confid
intern
consid
statist
signific
total
hospit
patient
surviv
deceas
enrol
studi
detail
laboratori
paramet
correl
analysi
perform
via
nonparametr
spearman
correl
test
graph
r
p
indic
correl
coeffici
pvalu
signific
respect
level
signific
indic
follow
ns
signific
p
p
p
p
clinic
inform
patient
includ
studi
shown
tabl
consist
result
previou
report
sex
bia
deceas
surviv
patient
p
median
age
deceas
individu
greater
surviv
individu
p
furthermor
deceas
sft
patient
show
significantli
higher
viral
load
higher
level
ast
ck
creatinin
lower
monocyt
percentag
compar
surviv
patient
signific
differ
deceas
surviv
sft
patient
respect
total
platelet
monocyt
lymphocyt
neutrophil
leukocyt
count
admiss
although
percentag
number
lymphocyt
significantli
differ
deceas
surviv
patient
tabl
supplementari
fig
number
lymphocyt
percentag
surviv
patient
dramat
lower
acut
recoveri
phase
compar
healthi
control
supplementari
fig
evalu
correl
lymphocyt
level
includ
cell
cell
viral
load
sftsi
analys
percentag
number
lymphocyt
variou
phase
sft
patient
via
flow
cytometri
data
surviv
patient
show
percentag
number
cell
significantli
decreas
acutephas
patient
compar
healthi
control
recoveryphas
patient
fig
furthermor
compar
surviv
patient
number
cell
percentag
admiss
significantli
decreas
deceas
patient
fig
howev
signific
correl
number
percentag
cell
viral
load
sftsi
fig
analys
chang
cell
cell
sft
patient
data
surviv
patient
show
percentag
number
cell
significantli
decreas
acutephas
patient
compar
healthi
control
recoveryphas
patient
fig
addit
number
percentag
cell
significantli
decreas
acutephas
patient
compar
healthi
control
recoveryphas
patient
fig
addit
compar
surviv
patient
deceas
patient
display
lower
percentag
number
cell
cell
admiss
fig
h
may
suggest
tcell
deplet
could
major
caus
tlymphocyt
defici
deceas
patient
addit
although
ratio
lower
deceas
patient
signific
differ
compar
surviv
patient
supplementari
fig
ratio
show
signific
correl
diseas
sever
supplementari
fig
linear
regress
analys
show
signific
correl
percentag
number
cell
cell
viral
load
sft
patient
fig
c
howev
percentag
number
cell
neg
correl
sftsi
fig
f
shown
fig
surviv
patient
percentag
number
cell
return
normal
level
day
day
respect
deceas
patient
percentag
number
cell
significantli
decreas
day
diseas
onset
compar
surviv
patient
return
normal
level
death
number
percentag
cell
significantli
correl
sever
sft
examin
frequenc
tcell
subset
sft
patient
infect
via
flow
cytometri
evalu
correl
frequenc
tcell
subset
sftsi
admiss
via
linear
regress
analys
data
surviv
patient
show
percentag
cell
treg
increas
acutephas
patient
compar
healthi
control
left
panel
fig
addit
shown
right
panel
fig
number
cell
increas
recoveryphas
patient
compar
acutephas
patient
healthi
control
signific
differ
acutephas
patient
healthi
control
note
number
cell
increas
acuteand
recoveryphas
patient
compar
healthi
control
fig
right
howev
number
treg
lower
acutephas
patient
compar
healthi
control
recoveryphas
patient
fig
right
addit
compar
surviv
patient
deceas
patient
display
increas
percentag
treg
cell
admiss
left
panel
fig
e
e
howev
number
treg
cell
measur
admiss
significantli
decreas
deceas
patient
compar
surviv
patient
right
panel
fig
e
e
furthermor
percentag
treg
significantli
posit
correl
sftsi
fig
number
treg
significantli
invers
correl
sftsi
fig
similar
result
observ
dynam
data
percentag
number
tcell
subset
deceas
surviv
patient
compar
surviv
patient
percentag
significantli
increas
day
percentag
treg
cell
significantli
increas
day
paramet
monitor
indic
time
point
entir
hospit
stay
patient
dash
line
repres
median
uninfect
control
data
shown
median
ci
statist
analysi
perform
use
mannwhitney
u
test
wilcoxon
match
pair
test
level
signific
indic
follow
ns
signific
p
p
p
p
respect
deceas
patient
left
panel
fig
g
g
furthermor
agreement
cell
defici
number
treg
decreas
day
diseas
onset
deceas
patient
compar
surviv
patient
right
panel
fig
g
g
fine
balanc
cell
treg
play
import
role
develop
infecti
diseas
investig
ratio
sft
patient
admiss
shown
fig
e
percentag
cell
posit
correl
percentag
treg
respect
howev
data
surviv
patient
show
ratio
markedli
increas
acuteand
recoveryphas
sft
patient
compar
healthi
control
fig
f
respect
addit
compar
surviv
patient
deceas
patient
exhibit
lower
ratio
higher
ratio
fig
g
respect
similar
result
observ
dynam
data
ratio
deceas
surviv
patient
fig
h
addit
linear
regress
analys
show
ratio
neg
posit
correl
sftsi
respect
fig
previou
studi
demonstr
host
cytokin
storm
associ
sever
sft
thu
evalu
correl
ratio
cytokin
includ
admiss
via
linear
regress
analys
consist
previou
studi
deceas
patient
display
increas
level
admiss
compar
surviv
patient
supplementari
fig
addit
linear
regress
analys
show
level
posit
correl
ratio
right
panel
fig
howev
signific
correl
level
ratio
left
panel
fig
although
sever
studi
immun
cell
mediat
human
mice
mechan
sftsv
caus
sever
ill
remain
elucid
data
indic
decreas
percentag
number
cell
decreas
number
treg
associ
increas
sever
sft
addit
increas
percentag
treg
residu
cell
well
skew
ratio
may
caus
poor
outcom
sft
patient
moreov
ratio
posit
correl
level
il
data
demonstr
lymphopeniaand
tcell
deplet
particularwa
commonli
observ
earli
cours
sftsv
infect
especi
patient
die
find
consist
result
previou
report
sft
viral
infect
addit
percentag
number
cell
cell
neg
correl
sever
sft
previou
studi
shown
deplet
cell
cell
result
delay
pulmonari
viral
clearanc
cell
requir
gener
optim
antibodi
respons
follow
infect
coronaviru
vaccinia
viru
moreov
absenc
cell
shown
compromis
product
primari
cytotox
lymphocyt
ctl
respons
follow
infect
vaccinia
viru
hsv
overal
dramat
loss
cell
deceas
patient
may
limit
initi
mainten
effect
humor
cytotox
tcell
immun
lead
immunosuppress
line
observ
deplet
cell
number
treg
also
lower
deceas
patient
compar
surviv
patient
cell
play
signific
role
antibacteri
antivir
immun
defenc
protect
humor
respons
addit
sever
studi
shown
adopt
transfer
either
cell
effici
boost
gener
neutral
antivir
igg
respons
accordingli
separ
studi
sft
patient
suggest
patient
sever
diseas
produc
lower
level
igg
igm
antibodi
earli
infect
patient
mild
form
diseas
although
percentag
cell
increas
acut
phase
patient
eventu
die
diseas
decreas
count
cell
may
impact
function
cellular
humor
immun
respons
thu
affect
viral
remov
addit
treg
shown
limit
patholog
viral
infect
includ
west
nile
viru
respiratori
syncyti
viral
infect
howev
data
observ
clinic
studi
indic
increas
treg
cell
ratio
bronchoalveolar
lavag
fluid
balf
obtain
acut
respiratori
distress
syndrom
ard
patient
time
admiss
independ
risk
factor
mortal
addit
decreas
number
treg
deceas
patient
may
decreas
function
thu
limit
magnitud
immun
respons
pathogen
control
inflammatori
reaction
interestingli
dynam
data
suggest
unlik
tcell
subset
number
cell
higher
earli
infect
deceas
patient
surviv
patient
previou
studi
indic
upregul
antiapoptot
molecul
thu
increas
persist
infect
inhibit
apoptosi
infect
cell
desensit
target
cell
kill
effector
cell
addit
studi
suggest
cell
mediat
tissu
inflamm
support
neutrophil
recruit
surviv
induc
express
proinflammatori
cytokin
word
lower
number
treg
cell
rel
higher
number
cell
statist
analysi
perform
via
nonparametr
spearman
correl
test
graph
r
p
indic
correl
coeffici
pvalu
signific
respect
level
signific
indic
follow
ns
signific
p
p
p
p
may
affect
direct
antivir
function
cell
provid
assist
b
cell
regul
immunopatholog
mediat
cytotox
kill
virusinfect
cell
addit
observ
tcell
deplet
cellular
microenviron
alter
deceas
patient
given
nonsynchron
chang
th
treg
cell
use
ratio
defin
relationship
inflamm
statu
regulatori
condit
immun
system
studi
demonstr
peripher
blood
ratio
decreas
ratio
increas
deceas
patient
compar
patient
surviv
previou
studi
suggest
bia
relat
pathogenesi
respiratori
syncyti
viru
rsv
bronchiol
infect
sever
human
mice
howev
studi
shown
ratio
potenti
predict
death
addit
sever
studi
indic
imbal
significantli
correl
sever
traumat
haemorrhag
shock
ard
patient
furthermor
similar
previou
studi
relat
hepat
b
viru
hbv
relat
acuteonchron
liver
failur
achblf
patient
ard
patient
increas
ratio
associ
surviv
sft
patient
moreov
data
show
increas
ratio
associ
increas
level
previou
studi
suggest
treg
imbal
occur
rheumatoid
arthriti
ra
patient
could
correct
tocilizumab
tcz
mediat
blockad
signal
associ
improv
clinic
outcom
addit
respons
suppress
treg
cell
patient
respond
treatment
adalimumab
inhibitor
via
control
monocytederiv
product
given
decreas
cell
ratio
increas
ratio
associ
diseas
sever
increas
number
cell
rectifi
bia
may
help
maintain
immun
system
steadi
state
thu
produc
therapeut
benefit
best
knowledg
studi
provid
first
kinet
data
subset
cell
sftsv
infect
also
first
studi
emphas
tcell
loss
bia
significantli
correl
sever
sft
data
shed
light
develop
diseas
contribut
better
understand
mechan
underli
progress
sft
data
may
major
signific
develop
therapeut
strategi
near
futur
elucid
potenti
factor
lead
decreas
tcell
number
bia
observ
deceas
sft
patient
present
studi
requir
addit
investig
supplementari
data
articl
found
onlin
http
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
lmm
zwj
pc
zx
substanti
contribut
concept
design
project
interpret
lmi
zyf
xy
xse
zcc
xlq
lbi
respons
acquisit
analysi
interpret
data
lj
lmj
ydl
guid
work
author
contribut
revis
manuscript
approv
final
version
author
declar
conflict
interest
thank
donor
patient
particip
research
studi
support
nation
natur
scienc
foundat
china
wuhan
union
hospit
faculti
graph
r
p
indic
correl
coeffici
pvalu
signific
respect
level
signific
indic
follow
ns
signific
p
p
p
p
research
fund
huazhong
univers
scienc
technolog
fund
sourc
play
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
